Ischemic Stroke

assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome

blood biomarkers

Cardio-embolic Stroke and Blood Bio-markers

Cardio-embolic Stroke and Blood Bio-markers:Diagnosis and Predictors of Short Term Outcome.

ranging from zero(no symptoms at all) to 6 (dead).outcome was defined as good if mRS=0-2,bad (poor) if mRS=3-5 and death if mRS=6

Wafaa Samir

Assistant professor of neurology

Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, q 8 hours for 3 days.
Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days.

Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.

Stroke, Ischemic

Hydrogen will be infused into bags of normal saline solution and administered intravenously, or infused into water for the patient to drink, as the patient's condition permits. This will be administered q 8 hours for 3 days.

Hydrogen

Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.
Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period.

Minocycline

Normal saline solution or water will be administered i.v. or p.o. respectively, in place of hydrogen solution.

Placebo Hydrogen

Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.

Placebo Minocycline

Stony Brook University Hospital

Neuroprotection in Acute Ischemic Stroke

Pilot Study of the Neuroprotective Effects of Hydrogen and Minocycline in Acute Ischemic Stroke

rating scale to assess level of functional independence for patients post-stroke. Scores range from 0 (no symptoms) to 6 (dead).

15-item neurologic examination scale for severity of stroke. Ratings for each item are scored with 3 to 5 grades. A total NIHSS of 0 is normal; 1-4 is considered a minor stroke; 5-15 moderate; 16-20 moderate to severe; and 21-42 severe.

Adrian Marchidann

Assistant Professor, Neurology Dept.

Stony Brook University

Korea Institute of Science and Technology

Disease activity score(DAS28) matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .
Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound.

Disease activity score(DAS28) Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.
Cardiac assessment :
By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound.

blood and serum samples separated br centrifugation

Rheumatoid Arthritis

MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound

Doxycycline Tablets

Assiut University

Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial

Efficacy of Doxycycline as a Combination Therapy in the Treatment of Rheumatoid Arthritis

percentage of patients achieving remission or low disease activity as assessed by DAS28

Eman Mohammed Ibrahem Kamel

principal investigator

A group of patients will receive methotrexate only, another group will receive methotrexate plus doxycycline

matching placebo medication for the control group

Chronic Kidney Disease

Cardiovascular Disease

All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.

proteinase/moždani udar

Cardio-embolic Stroke and Blood Bio-markers

Neuroprotection in Acute Ischemic Stroke

Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial

Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

Najkompletnija baza ljekovitog bilja potpomognuta naukom